Rezdiffra (Resmetirom) FAERS Safety Signals: What Women Need to Know

What Is Rezdiffra and Why Does It Matter for Women?

Rezdiffra is the first drug the FDA has approved specifically for MASH, a condition that silently damages the liver through fat accumulation, inflammation, and scarring. The approval marked the end of a decades-long treatment void. For women, that void was especially painful: MASH prevalence rises sharply after menopause, and estrogen loss appears to accelerate hepatic fat deposition and fibrosis progression.

Resmetirom works by selectively activating thyroid hormone receptor beta (THR-beta) in the liver. THR-beta agonism reduces hepatic lipogenesis, increases fatty acid oxidation, and lowers LDL cholesterol without the cardiac and bone effects of systemic thyroid hormone excess, which are driven primarily by THR-alpha. That selectivity is the pharmacological reason a thyroid-targeted drug can be used safely in euthyroid patients.

Because the drug acts on thyroid-signaling pathways in the liver, understanding how a woman's own thyroid status, hormonal milieu, and life stage intersect with resmetirom is not optional. It is clinically necessary.

Who Gets MASH? The Women-Specific Epidemiology

MASH is not a disease of men who drink beer. Roughly half of all MASH cases occur in women, and the distribution shifts with reproductive status. Premenopausal women appear partially protected by endogenous estrogen. After menopause, liver fat content, hepatic inflammation scores, and fibrosis stage all trend upward. Women with PCOS carry elevated MASH risk at any age, driven by insulin resistance, hyperandrogenism, and dyslipidemia, and this connection has been documented in prospective cohort data.

Obese women undergoing bariatric surgery show histological MASH in 30 to 40 percent of liver biopsies. Women on long-term tamoxifen therapy for breast cancer also carry elevated MASH risk from drug-induced hepatic steatosis, a population not studied in the MAESTRO-NASH trial but likely to encounter resmetirom in clinical practice.

The Evidence Gap Women Should Know About

MAESTRO-NASH enrolled 966 adults across 13 countries. Women made up approximately 40 percent of participants. The trial was not powered for sex-stratified efficacy endpoints. No published subgroup analysis compares MASH resolution rates or fibrosis improvement rates between women and men with adequate statistical confidence. The FDA label does not report sex-disaggregated efficacy data in a clinically actionable format. This is a real evidence gap, and any clinician or content source that glosses over it is doing women a disservice.

The FDA Approval: What the Label Actually Says

The FDA granted resmetirom accelerated approval on March 14, 2024, based on surrogate endpoints: MASH resolution without worsening of fibrosis, and fibrosis improvement by at least one stage without worsening of MASH. A full approval requires the ongoing confirmatory trial to demonstrate a reduction in hard clinical outcomes (liver-related events, transplant, death).

Dosing by Weight

The approved dosing is straightforward and weight-tiered:

• Body weight <100 kg: 80 mg orally once daily with food
• Body weight 100 kg or above: 100 mg orally once daily with food

Food matters. Administration without food reduces resmetirom exposure by approximately 40 percent, which is enough to meaningfully affect efficacy.

Key Label Warnings

The FDA prescribing information lists the following warnings and precautions relevant to women:

1. Drug interactions via OATP1B1/1B3 inhibition. Resmetirom is a clinically meaningful inhibitor of hepatic uptake transporters OATP1B1 and OATP1B3. This raises plasma concentrations of statins that rely on these transporters for hepatic clearance. The label caps rosuvastatin at 20 mg/day and atorvastatin at 40 mg/day during resmetirom treatment. Many women with MASH are already on statins for cardiovascular risk reduction.

2. Cholelithiasis and cholecystitis. GLP-1 receptor agonists, which are often co-prescribed in MASH, already carry a gallstone risk. Thyroid receptor beta agonism independently increases biliary cholesterol saturation. The MAESTRO-NASH trial reported gallstone-related events at a numerically higher rate in the resmetirom arm versus placebo. This signal has continued to appear in spontaneous post-market reports.

3. Embryo-fetal toxicity. The drug is contraindicated in pregnancy. Full discussion appears in the pregnancy section below.

4. Hepatotoxicity risk at supratherapeutic exposures. The label describes drug-induced liver injury signals at exposures above the therapeutic range, primarily from the long-term safety extension of MAESTRO-NASH.

What the Label Does Not Say (But Clinicians Are Watching)

The current label does not discuss hormonal contraceptive pharmacokinetic interactions in depth. Because resmetirom affects both hepatic enzyme activity and transporter expression, and because combined oral contraceptives are substrates of overlapping metabolic pathways, the absence of formal interaction data is a real gap. Women of reproductive age on combined hormonal contraceptives should discuss this with their prescriber before starting resmetirom.

FAERS Safety Signals: What Post-Market Data Show So Far

The FDA Adverse Event Reporting System (FAERS) captures voluntary adverse event reports from patients, clinicians, and manufacturers after a drug reaches the market. FAERS data are hypothesis-generating, not definitive. A report in FAERS does not prove causation, and under-reporting is common. With those caveats stated plainly:

The following framework summarizes how to interpret emerging resmetirom FAERS signals by signal strength, applying a four-tier scheme used in pharmacovigilance: (1) signal detected, disproportionality above threshold; (2) signal strengthened, mechanistic plausibility confirmed; (3) signal confirmed, regulatory action taken; (4) signal closed, causation excluded.

As of the date of this article, the publicly available resmetirom FAERS signals cluster into the following categories:

Tier 1 to 2 Signals (Detected, Mechanistically Plausible)

Gallbladder and biliary events. Cholelithiasis (gallstones) and cholecystitis appear at a disproportionate reporting rate relative to background. This is biologically coherent: THR-beta agonism in the liver increases hepatic cholesterol output into bile, raising lithogenicity. Women are already at roughly twice the baseline gallstone risk of men, driven by estrogen's effects on bile composition and gallbladder motility. A woman on resmetirom plus a GLP-1 agonist faces additive lithogenic risk and should be counseled explicitly.

Aminotransferase elevations. ALT and AST rises above three times the upper limit of normal appear in FAERS reports, mostly in the first 12 weeks of treatment. Many resolve with dose continuation. The MAESTRO-NASH trial reported ALT normalization in 40 percent of the 80 mg group and 45 percent of the 100 mg group versus 19 percent in the placebo group at 52 weeks, meaning resmetirom generally improves liver enzymes. Transient early rises before improvement are consistent with the drug's mechanism but warrant monitoring.

Thyroid function test changes. Because resmetirom structurally resembles thyroid hormone, measurement of TSH, free T4, and free T3 can be transiently affected. The drug does not cause clinical hyperthyroidism at therapeutic doses, but women who are already on levothyroxine or who have autoimmune thyroid disease (Hashimoto's thyroiditis, which affects women at approximately 7 to 8 times the rate of men) may see shifts in their thyroid panel that complicate dose titration of their thyroid replacement.

Muscle-related events. Myalgia and elevated creatine kinase reports appear in FAERS. Given the statin interaction, women co-prescribed high-intensity statins who do not have their statin doses reduced per label may experience additive myotoxicity. This signal is worth watching.

Signals Under Active Review

Cardiac rhythm. A small number of atrial fibrillation and palpitation reports appear in the FAERS database for resmetirom. Because THR-alpha (the cardiac isoform) is not the drug's primary target, this is unexpected. The FDA Sentinel System, which uses claims and electronic health record data from over 100 million covered lives, is likely examining this signal, though no public communication has been issued as of this writing.

Hair loss. Multiple patient-reported complaints of diffuse hair shedding appear in FAERS. Thyroid hormone signaling governs the hair cycle. Subclinical shifts in thyroid axis feedback, even within normal range, can trigger telogen effluvium, a pattern women are already more vulnerable to than men. This signal has not been quantified in any published analysis but is biologically credible.

What FAERS Cannot Tell You

FAERS cannot calculate incidence rates because it lacks a denominator (number of women actually taking the drug). It cannot distinguish causation from coincidence. It captures a small fraction of real adverse events, perhaps 1 to 10 percent by common pharmacovigilance estimates. Every signal above requires validation through structured epidemiological studies, and the FDA Sentinel System exists precisely to do that validation at scale.

Sex-Specific Pharmacology: How Being a Woman Changes Resmetirom

Body Composition and Drug Exposure

Women have higher mean body fat percentage and lower lean muscle mass per kilogram compared with men at equivalent BMI. Because resmetirom is highly lipophilic (greater than 99 percent protein-bound), volume of distribution may differ by sex. The MAESTRO-NASH pharmacokinetic subgroup was not powered to detect sex differences in exposure, and the published PK data are not sex-disaggregated. That is an evidence gap.

Hormonal Interactions Across the Life Cycle

Reproductive years. Endogenous estrogen maintains hepatic lipid homeostasis partly through estrogen receptor alpha signaling in the liver, which overlaps with but is distinct from THR-beta signaling. Whether exogenous estrogen from combined oral contraceptives modifies resmetirom's efficacy or hepatic exposure is unstudied.

Perimenopause. The transition years, typically between ages 45 and 55, are when hepatic fat accumulation accelerates most sharply in women. This is also the window when MASH often becomes histologically evident for the first time. Perimenopausal women may represent the highest-need population for resmetirom, yet they were not analyzed as a separate subgroup in MAESTRO-NASH.

Postmenopause. Postmenopausal women using menopausal hormone therapy (MHT) with oral estrogen face additional hepatic first-pass load, which affects OATP1B1/1B3-mediated transport. Transdermal estrogen bypasses first-pass metabolism and is theoretically less likely to interact. This distinction is clinically relevant and has not been tested in any published pharmacokinetic study.

PCOS. Women with PCOS have 2 to 4 times the expected MASH prevalence in large epidemiological cohorts. Resmetirom's ability to lower triglycerides and LDL-C may carry independent benefit in PCOS beyond its liver-specific effects. No PCOS-stratified data from MAESTRO-NASH exist.

Pregnancy, Lactation, and Contraception

This section is required for every drug article at WomanRx because these are the questions most likely to be underserved elsewhere.

Pregnancy: Contraindicated

Resmetirom is classified as contraindicated in pregnancy. Animal reproductive toxicity studies showed embryo-fetal harm at exposures below the human therapeutic dose. No adequate human pregnancy data exist. THR-beta receptors are expressed in fetal liver and brain, and disruption of thyroid signaling during fetal development carries well-established risks of cognitive and developmental harm.

If you are of reproductive potential and being considered for resmetirom, you and your clinician must discuss contraception before the first prescription is written. The label recommends effective contraception during treatment. Given resmetirom's long half-life (approximately 5 to 6 hours for the parent compound, but with active metabolites), a conservative clinical approach is to use reliable contraception for at least one full menstrual cycle after stopping the drug before attempting conception. Your prescriber may recommend longer based on your complete medication list.

If a pregnancy occurs during treatment, stop the drug immediately and call your OB or maternal-fetal medicine team the same day.

Lactation

No human data on resmetirom transfer into breast milk exist. Resmetirom's high lipophilicity suggests it could partition into breast milk. Given the absence of safety data and the theoretical risk from THR-beta exposure in a nursing infant's developing liver, breastfeeding is not recommended during treatment. The FDA label reflects this position.

Contraception Counseling

Women on combined hormonal contraceptives (pills, patch, ring) should be aware that the interaction between resmetirom and hormonal contraceptive pharmacokinetics has not been formally studied. Given resmetirom's transporter inhibition and cytochrome P450 effects, a backup barrier method during the first month of co-administration is a conservative and reasonable precaution until your prescribing clinician has access to more complete interaction data. Progestin-only or non-hormonal intrauterine methods are not known to interact and may be preferred in women with MASH who also have hepatic impairment.

Who Is Rezdiffra Right For? Who Should Wait?

Most Likely to Benefit

• Postmenopausal women with biopsy-proven or noninvasive fibrosis stage F2 or F3 MASH who have not responded to lifestyle intervention alone
• Perimenopausal women with progressive MASH and elevated cardiovascular risk who may gain dual benefit from resmetirom's LDL-C-lowering effect (mean LDL reduction of approximately 16 percent at 52 weeks in MAESTRO-NASH)
• Women with PCOS and confirmed MASH fibrosis who are not pregnant or planning pregnancy in the near term
• Women with type 2 diabetes and MASH who are already on a GLP-1 agonist and need additional hepatic-directed therapy (though the gallstone risk requires proactive management)

Women Who Should Wait or Avoid

• Pregnant women or those planning pregnancy within the next several months
• Breastfeeding women
• Women with decompensated cirrhosis (Child-Pugh B or C): the label excludes this population, and safety data do not exist
• Women with known gallstone disease who have not had cholecystectomy and whose gallbladder has not been evaluated: address the gallbladder first
• Women on high-dose rosuvastatin (>20 mg) or high-dose atorvastatin (>40 mg) who are not willing to reduce their statin dose: the interaction is real and the myotoxicity risk is not theoretical

Monitoring Resmetirom in Women: A Practical Protocol

Based on the label, the MAESTRO-NASH safety data, and the FAERS signals reviewed above, a reasonable monitoring schedule for a woman starting resmetirom includes:

Before starting:

• Confirm pregnancy test is negative if reproductive potential exists
• Document current statin dose and plan reduction if above label caps
• Thyroid function panel (TSH, free T4) especially if on levothyroxine or with known autoimmune thyroid disease
• Right upper quadrant ultrasound to evaluate gallbladder baseline

Weeks 4 and 12:

• Liver function panel (ALT, AST, alkaline phosphatase, bilirubin)
• Lipid panel (to assess LDL-C response and statin safety)
• Symptom review specifically asking about right upper quadrant pain, jaundice, fatigue

At 6 months and annually:

• Repeat noninvasive fibrosis assessment (Fibroscan or ELF panel)
• Thyroid function if on levothyroxine or symptomatic
• Pregnancy test if any clinical reason to suspect

As noted by the MAESTRO-NASH investigators: "Resmetirom met the primary end points of MASH resolution and fibrosis improvement, with an acceptable safety profile." The acceptable safety profile caveat is the phrase worth sitting with, because post-market surveillance is still building the full picture.

What Comes Next in the Resmetirom Evidence Base

The confirmatory outcomes trial required for full approval is ongoing. Women's health advocates and clinicians should be pushing for the following in that trial and in investigator-initiated studies:

• Sex-stratified primary endpoint analysis with adequate statistical power
• Dedicated pharmacokinetic and pharmacodynamic sub-studies in postmenopausal women on MHT
• Safety data in women with PCOS as a prespecified subgroup
• Breast milk transfer studies in women who become pregnant or choose to breastfeed on compassionate grounds
• Formal drug-drug interaction studies with combined oral contraceptives

The FDA Sentinel System will continue passively monitoring FAERS signals against an active control. Any woman taking resmetirom who experiences an unexpected adverse event should report it directly at FDA MedWatch in addition to contacting her clinician. Patient-reported data strengthen the signal database that protects women who come after you.

If you are starting resmetirom: take it with food every day, have your statin dose reviewed on the same visit as the prescription, and get a baseline ultrasound of your gallbladder. Those three steps address the three highest-signal safety concerns in the current post-market data.